Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming false Single Family Member false Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

FP:(EBOLA)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

51.20200261389PROTECTIVE METALLOTHIONEIN ANALOG COMPOUNDS, THEIR COMPOSITIONS AND USE THEREOF IN THE TREATMENT OF PATHOGENIC DISEASES
US 20.08.2020
Int.Class A61K 31/198
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
197the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
198Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
Appl.No 16858505 Applicant Albert Crum Inventor Albert Crum

Embodiments of the present invention relate generally the use of certain compositions, e.g., compositions comprising a glutathione precursor and a selenium source, in the therapy of viral diseases and/or reducing the incidence of viral diseases. Related embodiments of the present invention relate to treatment and/or reducing the incidence of respiratory ailments caused by respiratory syncytial virus (RSV) or hemorrhagic fever (EHF) caused by Ebola viruses (EBV) or Marburg virus. Yet in other embodiments, the invention relates to reducing metal toxicity in a biological system, which involves contacting the biological system with a composition comprising a glutathione precursor and a selenium source, optionally together with a chelating agent, an antioxidant, a metallothionein protein or a fragment of metallothionein.

52.3695844METHODS FOR TREATING NIPAH VIRUS INFECTIONS
EP 19.08.2020
Int.Class A61K 31/706
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
Appl.No 20152978 Applicant GILEAD SCIENCES INC Inventor CHUN BYOUNG KWON
Provided are compounds, methods, and pharmaceutical compositions for treatingFiloviridaevirus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV:The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.
53.111548411Monoclonal antibody for neutralizing EB virus and application thereof
CN 18.08.2020
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
Appl.No 202010362347.6 Applicant SUN YAT-SEN UNIVERSITY CANCER CENTER (SUN YAT-SEN UNIVERSITY AFFILIATED CANCER HOSPITAL, SUN YAT-SEN UNIVERSITY CANCER INSTITUTE) Inventor ZENG MUSHENG
The invention discloses an EB virus antibody for the first time, which consists of a light chain and a heavy chain, a heavy chain variable region of the heavy chain is provided with three complementary regions CDR1, CDR2 and CDR3; the amino acid sequences of the light chain are respectively shown as SEQ ID NO.1-3, the light chain variable region of the light chain is provided with three complementary regions CDR1 ', CDR2' and CDR3 ', and the amino acid sequences of the light chain variable region of the light chain are respectively shown as SEQ ID NO.4, GAS and SEQ ID NO.5. The antibody can block EBV from infecting epithelial cells, IC50 is 53 ng/ml, and the antibody has no neutralizing effect on Ebola virus infection, which indicates that the antibody has very high capacity of specifically neutralizing EBV infected epithelial cells.
54.202017019418N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO
IN 14.08.2020
Int.Class A61K 31/706
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
Appl.No 202017019418 Applicant EMORY UNIVERSITY Inventor PAINTER, George, R.
This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections, such as Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infection with the disclosed compounds.
55.2020120683HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEINS
JP 13.08.2020
Int.Class Appl.No 2020081768 Applicant REGENERON PHARMACEUTICALS INC Inventor CHRISTOS KYRATSOUS

PROBLEM TO BE SOLVED: To provide human antibodies to Ebola virus glycoproteins.

SOLUTION: The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to Ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies, and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing Ebola virus activity, thus providing means of treating or preventing Ebola virus infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the Ebola virus for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.

SELECTED DRAWING: None

COPYRIGHT: (C)2020,JPO&INPIT

56.111514123Applications of tiluotong analogues in anti-viral infection
CN 11.08.2020
Int.Class A61K 31/15
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
15Oximes ; Hydrazines ; Hydrazones
Appl.No 202010097145.3 Applicant JIANGSU BERKGEN BIO-PHARMACY CO., LTD. Inventor WANG FEI
The present invention provides applications of tiluotong analogues in anti-viral infection. Specifically, the present invention relates to uses of the tiluotong analogues in preparing medicines for prevention and/or treatment of coronavirus, influenza virus, parainfluenza virus, cytomegalovirus, adenovirus, rhinovirus, herpes simplex, varicella-zoster, rubella virus, measles virus, dengue virus, yellow fever virus, West Nile virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, enterovirus, respiratory syncytial virus and Ebola virus, and relates to a pharmaceutical composition for prevention and/or treatment of the above-mentioned viral infection. Preferably, the coronavirus is 2019-novel coronavirus (2019-nCoV).
57.111518815Universal Ebola virus disease immunoglobulin as well as preparation method and application thereof
CN 11.08.2020
Int.Class C12N 15/40
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
Appl.No 202010121145.2 Applicant INSTITUTE OF MILITARY VETERINARY MEDICINE, ACADEMY OF MILITARY SCIENCES Inventor ZHAO YONGKUN
The invention provides universal Ebola virus disease immunoglobulin as well as a preparation method and application thereof. The method comprises the following steps of firstly, analyzing Zaire type,Sudan type and CotedIvoire type Ebola virus genomes, and optimizing Ebola virus GP and VP40 genetic sequences to form chimeric virus particle type sequences, so that the chimeric virus particle type sequences can completely cover main epitopes of viruses III; then, expressing, purifying and preparing Ebola chimeric virus-like particle vaccine antigens by using an insect-rhabdovirus expression system and a vaccinia virus recombinant living vector vaccine system; and finally, immunizing an animal to obtain high-immunity plasma, carrying out pepsin digestion, ammonium sulfate precipitation and chromatographic column purification to obtain the high-purity anti-Ebola virus disease immunoglobulin F(ab')2, and carrying out safety and effectiveness evaluation on the high-purity anti-Ebola virus disease immunoglobulin. The universal Ebola virus disease immunoglobulin provided by the invention can prevent and treat hemorrhagic fever caused by Ebola virus III infection, and provides a powerful tool for Ebola epidemic prevention and control.
58.111481558Application of protoporphyrin derivatives in preparation of enveloped virus blocking agent
CN 04.08.2020
Int.Class A61K 31/555
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
555containing heavy metals, e.g. hemin, hematin, melarsoprol
Appl.No 202010284150.5 Applicant GUANGZHOU PEPMONT BIOTCH INC. Inventor HE JIAN
The invention discloses an application of protoporphyrin derivatives in preparation of an enveloped virus blocking agent. The inventor finds that protoporphyrin and derivatives thereof have broad-spectrum antiviral activity on LASV, MERS, Ebola, SARS-CoV-2, a series of influenza viruses of different subtypes and the like in in-vitro experiments, and the median inhibitory concentration is between 0.91 mu M and 1.88 mu M. The possible mechanism is that biophysical interaction with enveloped lipid of enveloped viruses is carried out, so that the enveloped lipid is inhibited from forming a negative bending configuration, and the fusion effect between virus envelopes and host cell membranes is blocked. Meanwhile, an animal in-vivo model of a mouse infected with an A/Puerto Rico/8/34 (H1N1) virus strain is preliminarily adopted to verify the antiviral effect of protoporphyrin, and results show that the survival rate and the survival time of mice in an administration group are obviously improved. These research results indicate that the inventor can set up an antiviral drug targeting virus envelopes by taking protoporphyrin as a lead compound so as to prevent and treat infectious diseasescaused by enveloped virus infection.
59.3684406FILOVIRUS VACCINE AND METHODS OF USE
EP 29.07.2020
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No 18854828 Applicant HAWAII BIOTECH INC Inventor CLEMENTS DAVID E
The data reported herein describe the production and evaluation of a recombinant subunit filovirus vaccine using insect cell expressed surface glycoprotein (GP) and a highly effective adjuvant. The vaccine provides protection in humans against filovirus infection, including Ebola virus and Marburg virus.
60.WO/2020/148554ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
WO 23.07.2020
Int.Class A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Appl.No PCT/GB2020/050103 Applicant UCB BIOPHARMA SRL Inventor LIGHTWOOD, Daniel John
The invention relates to antibodies that bind to the Ebola virus glycoprotein, particularly to antibody cocktails comprising a number of such antibodies. The antibodies and cocktails may be used to treat, prevent or ameliorate Ebola virus infection.